Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

← catalyst calendar

NCT06750276 · results posted

Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.

Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
40actual
Sites
9
Countries
Puerto Rico, United Kingdom, United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2024-12-06actualWhen the study began enrolling
Primary completion2025-07-28actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-07-28actualThe whole study's end, after follow-up
First posted2024-12-27actualWhen this record first appeared on the registry
Results posted2026-07-06actualWhen the sponsor posted results to the registry
Record updated2026-07-06actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • Liver Fibrosis
  • Hepatic Cirrhosis

Intervention

  • Drug: AZD2389

Primary outcomes

what the primary-completion date above is the date OF
Notable Trends in Laboratory Assessments (Haematology, Coagulation, Clinical Chemistry, Fibrinolysis, and Urinalysis)
measured From screening up to and including Day 35
Clinically Relevant Trends in Vital Signs (Blood Pressure, Pulse Rate, Oxygen Saturation, Body Temperature, and Respiration Rate), and 12-lead Electrocardiogram (ECG)
measured From Screening up to and including Day 35

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2025-04-17 · 3.8 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-09-10 · 2.0 MB · SAP_001.pdf

Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed